Free Trial

CNS Pharmaceuticals (CNSP) Competitors

CNS Pharmaceuticals logo
$0.93 +0.01 (+1.46%)
As of 09:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CNSP vs. BLRX, AYTU, BIVI, CGTX, JATT, QTTB, LPCN, CING, MTEX, and GELS

Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include BioLineRx (BLRX), Aytu BioPharma (AYTU), BioVie (BIVI), Cognition Therapeutics (CGTX), JATT Acquisition (JATT), Q32 Bio (QTTB), Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry.

CNS Pharmaceuticals vs. Its Competitors

CNS Pharmaceuticals (NASDAQ:CNSP) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CNS Pharmaceuticals currently has a consensus target price of $25.00, indicating a potential upside of 2,599.78%. BioLineRx has a consensus target price of $26.00, indicating a potential upside of 481.66%. Given CNS Pharmaceuticals' higher probable upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than BioLineRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNS Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
BioLineRx
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

CNS Pharmaceuticals has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

BioLineRx has higher revenue and earnings than CNS Pharmaceuticals. BioLineRx is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00
BioLineRx$28.94M0.66-$9.22M-$8.80-0.51

In the previous week, BioLineRx had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.75 beat BioLineRx's score of 0.22 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CNS Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLineRx
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CNS Pharmaceuticals has a net margin of 0.00% compared to BioLineRx's net margin of -15.21%. BioLineRx's return on equity of -23.93% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CNS PharmaceuticalsN/A -385.41% -193.20%
BioLineRx -15.21%-23.93%-6.80%

Summary

BioLineRx beats CNS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSP vs. The Competition

MetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.07M$2.88B$5.50B$8.94B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio0.0020.8026.9720.11
Price / SalesN/A287.03426.02119.76
Price / CashN/A41.1936.8257.86
Price / Book0.177.487.985.56
Net Income-$14.86M-$55.04M$3.16B$248.40M
7 Day Performance-1.48%2.44%2.36%4.67%
1 Month Performance-10.10%1.90%2.15%6.64%
1 Year Performance-98.20%4.35%33.78%21.31%

CNS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNSP
CNS Pharmaceuticals
1.6817 of 5 stars
$0.93
+1.5%
$25.00
+2,599.8%
-98.4%$5.07MN/A0.005News Coverage
BLRX
BioLineRx
2.6866 of 5 stars
$4.57
+3.2%
$26.00
+468.9%
-80.7%$18.88M$28.94M-0.5240
AYTU
Aytu BioPharma
3.7667 of 5 stars
$2.18
+3.8%
$12.00
+450.5%
-19.6%$18.85M$81M-3.03160Gap Up
High Trading Volume
BIVI
BioVie
0.6359 of 5 stars
$0.93
-8.4%
$3.00
+224.3%
+111.8%$18.76MN/A-0.1210Gap Up
CGTX
Cognition Therapeutics
2.8021 of 5 stars
$0.31
+3.3%
$5.63
+1,715.7%
-68.7%$18.60MN/A-0.4220Gap Up
JATT
JATT Acquisition
N/A$1.05
-8.7%
N/A-67.7%$18.11MN/A0.003Gap Up
High Trading Volume
QTTB
Q32 Bio
2.0313 of 5 stars
$1.49
+2.8%
$12.17
+716.6%
-92.7%$17.69M$1.16M-0.3039
LPCN
Lipocine
1.577 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-57.8%$17.60M$11.20M-3.1010
CING
Cingulate
2.7219 of 5 stars
$4.07
+0.5%
$26.00
+538.8%
+1,135.6%$17.19MN/A-0.4820News Coverage
Gap Up
MTEX
Mannatech
0.2811 of 5 stars
$9.35
+3.9%
N/A+17.5%$17.11M$117.87M-93.50250High Trading Volume
GELS
Gelteq
N/A$1.73
-4.4%
N/AN/A$17.08M$100K0.00N/AGap Up

Related Companies and Tools


This page (NASDAQ:CNSP) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners